Are angiotensin converting enzyme inhibitors and angiotensin receptor blockers becoming the treatment of choice in African-Americans?

Current Hypertension Reports

Volumn 4, Issue 4, 2002, Pages 286-289

  Fenves, Andrew ^a   Ram, C Venkata S ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

AFRICAN AMERICAN; DRUG ANTAGONISM; DRUG EFFECT; ETHNOLOGY; HUMAN; HYPERTENSION; NEGRO; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

AFRICAN AMERICANS; AFRICAN CONTINENTAL ANCESTRY GROUP; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; HUMANS; HYPERTENSION; RECEPTORS, ANGIOTENSIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 0036689963     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-996-0006-y     Document Type: Article

References (24)

1. Ram V, Fenves AZ: Hypertension. In Conn's Current Therapy, edn 52. Philadelphia: WB Saunders; 2000: 303-314.
2. Bakris GL, Mangrum A, Copley BJ, et al.: Effect of calcium channel or beta blockade and the progression of diabetic nephropathy in African Americans. Hypertension 1997, 29: 744-750.
3. Lufk FC, Miller JZ, Grim CE: Cell sensitivity and resistance of blood pressure, age, and race as factors in physiological responses. Hypertension 1991, 17(Suppl 1): 102-108.
4. Radevski I, Skudicky D, Candy G, et al.: Antihypertensive monotherapy with nisoldipine CC is superior to enalapril in black patients with severe hypertension. Am J Hypertens 1999, 12(2 Pt 1): 194-203.
5. National Heart, Lung, and Blood Institute: Disease statistics. In Fact Book Fiscal Year 1998. Bethesda, MD: National Institutes of Health; 1999: 31-48.
6. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Arch Intern Med 1997, 157: 2413-2446.
7. Burt VL, Whelton P, Roccella E, et al.: Prevalence of hypertension in the US adult population: results form the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension 1995, 25: 305-313.
8. Toto R: Angiotensin II subpart I receptor blockers and renal function. Arch Intern Med 2001, 161: 1492-1499.
9. U.S. Renal Data Systems: U.S. RDS 1999 Annual Data Report. Bethesda, MD: National Institutes of Health, National Institute of Diabetes, Digestive, and Kidney Disease; 1999.
10. Agodoa LY, Appel L, Backris GL, et al.: Effect of ramipril vs. amlodipine on renal outcomes in hypertensive nephrosclerosis. A randomized controlled trial. JAMA 2001, 285: 2119-2728.
11. Kaplan NM: Management of hypertension in patients with type II diabetes mellitus: guidelines based on current evidence. Ann Intern Med 2001, 135: 1079-1083.
12. Lewis EJ, Hunsicker LG, Clarke WR, et al.: Renal protective effect of the angiotensin receptor antagonist in patients with nephropathy due to type II diabetes. N Engl J Med 2001.
13. Crook ED, Harris J, Oliver B, Taylor R: The effect of enalapril on advanced diabetic nephropathy in African-American females. Ethnic Dis 2001, 11: 211-216.
14. Exner DV, Dries DL, Domanski MJ, Cohn JN: Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med 2001, 344: 1351-1357.
15. Jafar TH, Schmid CH, Landa M, Giatras I, et al.: Angiotensin converting enzyme inhibitors and progression of nondiabetic renal disease, a meta-analysis of patient level data. Ann Intern Med 2001, 135: 73-87.
16. Hillege HL, Janssen WM, Pinto-Sietsma SJ, et al.: Microalbuminuria, a better predictor for clinical outcome than hypertension and/or hypercholesterolemia [abstract 4113]? Circulation 2000, 102(suppl II): II-857.
17. Borch-Johnsen K, Feldt-Rasmussen B, Strandgaard S, et al.: Urinary albumin excretion: an independent predictor of ischemic heart disease. Arterioscler Thromb Vasc 1999, 19: 1992-1997.
18. Gibbs CR, Lip Gy, Beevers DG: Angioedema due to ACE inhibitors: increased risk in patients of African origin. Br J Clin Pharmacol 1999, 48: 861-865.
19. Levine B: Effect of eprosartan and enalapril in the treatment of black hypertensive patients: subgroup analysis of a 26-week, double-blind, multicentre study. Eprosartan Multinational Study Group. Curr Med Res Opin 1999, 15: 25-32.
20. Jamerson KA: Rationale for angiotensin II receptor blockers in patients with low-renin hypertension. Am J Kidney Dis 2000, 36(Suppl 1): S24-S30.
21. McGill JB, Reilly PA: Combination treatment with telmisartan and hydrochlorothiazide in black patients with mild to moderate hypertension. Clin Cardiol 2001, 24: 66-72.
22. The Heart Outcomes Prevention Evaluation Study Investigators: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000, 342: 145-153.
23. Bakris GL, Williams M, Dworkin L, et al., for the National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group: Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis 2000, 36: 646-661.
24. Sowers JR, Epstein M, Frohlich ED: Diabetes, hypertension, and cardiovascular disease: an update. Hypertension 2001, 37: 1053-1059.